Asuragen ( granted a nonexclusive license to Agendia ( for the company’s RNARetain for human diagnostic applications. “The tissue-preservative solution has found widespread clinical application and is uniquely suited for preserving nucleic acid profiles in solid tissues, both normal and cancerous, for subsequent clinical testing,” notes Matt Winkler, CEO of Asuragen.

Next articleUMMZ Periodical Cicada Page